Genmab — Maj 2020
-
Stock...og?
-
Rentschler Biopharma Extends Collaboration with Genmab to U.S. facility
-
Rentschler Biopharma Extends Collaboration with Genmab to U.S. facility - GlobeNewswire
27-May-2020 15:00:10For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200527:nGNX2tTlD1- Innovative agreement provides flexible model to address Genmab’s
development and manufacturing needs as programs advance in development - Rentschler Biopharma’s U.S. site expansion progressing on tra
- Innovative agreement provides flexible model to address Genmab’s
-
LAUPHEIM, Germany and MILFORD, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the company has entered into a strategic collaboration with Genmab for the process development and manufacture of bispecific antibodies generated with Genmab’s DuoBody
technology platform. This partnership uses an innovative business model which fits well with the expansion plans f -
Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, said: “We are excited to expand our strategic partnership with Genmab, a leading biotech specializing in the creation and development of differentiated antibody therapeutics, to our U.S. facility. In this new age of personalized medicine, breakthrough molecules, and complex therapies, Rentschler Biopharma welcomes the opportunity to use innovation to empower our clients and ultimately help patients. The work we
-
Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, said: “We are excited to expand our strategic partnership with Genmab, a leading biotech specializing in the creation and development of differentiated antibody therapeutics, to our U.S. facility. In this new age of personalized medicine, breakthrough molecules, and complex therapies, Rentschler Biopharma welcomes the opportunity to use innovation to empower our clients and ultimately help patients. The work we
-
The work we will do for Genmab at our U.S. site represents a first-of-its-kind collaboration that will involve several novel projects and enable the client to decide in a flexible and agile way which projects to advance and when.”
-
Så Genmab køber ingen fabrik i denne omgang
-
Enten ud af kanalen og vidre op eller retracement og så blive i kanalen indtil vi når kurs 3000 Maj 2022 https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/84416_Genmab_mod_kurs_3000.JPG
-
Cool, thx EL
-
Up, up and away!! ^^
-
Novo, Zeal, Bava, Ambu m.fl falder tungt i dag.
-
the Ofatumumab
Autoinjector trial completed -nicely on time https://clinicaltrials.gov/ct2/history/NCT03560739?A=13&B=14&C=merged#StudyPageTop -
Rentschler er bare en alm CRO deal. Alle selskaber har sådan nogle deals. Det er genmab der betaler en CRO for at producere små batches antistoffer til div prækliniske og kliniske forsøg. No news
-
Novartis' repurposed leukemia drug tops Sanofi's Aubagio in MS study weeks ahead of FDA verdict https://www.fiercepharma.com/pharma/novartis-repurposed-leukemia-drug-tops-sanofi-s-aubagio-ms-study-weeks-ahead-fda-verdict
-
ASCO: Stay alert. Fradag kl. 14 er der virtuelle præsentationer af Epcoritamab, Amivantamab, TV og Teclistamab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind